SLC5A2 and type 2 diabetes mellitus: Currently, even in the presence of high CV risk, ADA continues to support metformin as the first-line drug in T2DM, with consideration of concurrent therapy with SGLT2-Is in patients with HF or kidney disease and either SGLT2-Is or GLP1-RAs in patients with predominantly atherosclerotic CV disease (CVD) [9].